Join
Live feed
·
PRReleasevia Quantisnow
Entera Bio Ltd. logo

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress

ByQuantisnow·Wall Street's wire, on your screen.
ENTX· Entera Bio Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENTX (Entera Bio Ltd.) and more on Quantisnow.